![]() |
市場調査レポート
商品コード
919376
α1アンチトリプシン欠損症 (A1AD):パイプライン製品の分析Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020 |
α1アンチトリプシン欠損症 (A1AD):パイプライン製品の分析 |
出版日: 2020年08月31日
発行: Global Markets Direct
ページ情報: 英文 118 Pages
納期: 即納可能
![]() |
当レポートでは、世界各国におけるα1アンチトリプシン欠損症 (A1AD) のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline landscape.
Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide also reviews of key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 16, 3 and 2 respectively.
Alpha-1 Antitrypsin Deficiency (A1AD) (Other Diseases) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.